ABBV-295 another Amylin analog (IAPP)
-
ABBV-295 is an investigational, long-acting amylin analog developed by AbbVie and Gubra for the treatment of obesity. It acts as a non-incretin-based therapy by activating amylin and calcitonin receptors to suppress appetite and delay gastric emptying.
https://youtu.be/-vXtzFPE0Dc?is=JqfGC3HdP48X7HfQ
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Register Login